Printer Friendly

Emergent BioSolutions appoints Kathryn C. Zoon, PhD to board.

M2 EQUITYBITES-November 9, 2016-Emergent BioSolutions appoints Kathryn C. Zoon, PhD to board

(C)2016 M2 COMMUNICATIONS http://www.m2.com

Biopharmaceutical company Emergent BioSolutions (NYSE:EBS) disclosed on Tuesday the election of Kathryn C. Zoon, PhD to its board of directors.

Currently, Dr Zoon is a scientist emeritus with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH).

Previously at NIH, Dr Zoon served as chief of the Cytokine Biology Section (NIAID), director of the Division of Intramural Research (DIR/NIAID), deputy director for Planning and Development at the DIR/NIAID as well as principal deputy director of the Center for Cancer Research at the National Cancer Institute.

Earlier in her career, Dr Zoon worked as director of the Center for Biologics Evaluation and Research (CBER) for 10 years and director of the Division of Cytokine Biology in CBER, respectively, at the US Food and Drug Administration (FDA).

Additionally, Dr Zoon has been a member of the NIH Board of Scientific Directors since 1992, a member of the National Academy of Medicine since 2002 as well as has served on the World Health Organsation's Expert Committee on Biological Standards for almost two decades.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 9, 2016
Words:211
Previous Article:First Industrial Realty Trust announces dividend of UDS0.19 per share for quarter.
Next Article:Wyndham Worldwide announces dividend of USD0.50 per share.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters